Shares of genomics company Illumina (NASDAQ:ILMN) jumped 3.7% in the pre-market session after analysts at Robert W. Baird increased their price target on the life sciences company's stock to $105.00.

Image of Cathie Wood via Wikimedia Commons. In a market dominated by headlines about artificial intelligence (AI), cloud ...

Illumina (NASDAQ:ILMN) stock dips as Scotiabank downgrades. However, peers Danaher (DHR) stock and Thermo Fisher (TMO) stock win upgrades. Read more here.

Shares of genomics company Illumina (NASDAQ:ILMN) fell 4.2% in the morning session after a Citi analyst downgraded the stock to 'Sell' from 'Neutral' and lowered the price target.

The market expects Illumina (ILMN) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is ...

In a report released today, Daniel Brennan from TD Cowen maintained a Hold rating on Illumina, with a price target of $106.00. The company’s shares closed today at $96.94. Eleva ...

Analysts have given IQVIA Hldgs a total of 7 ratings, with the consensus rating being Neutral. The average one-year price target is $174.0, indicating a potential 8.32% upside.

Illumina has an analyst consensus of Moderate Buy, with a price target consensus of $107.73, which is a 10.6% upside from current levels. In a report issued on June 24, Barclays also maintained a Sell ...

Agenus (AGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road ...

Analysts William Tng and Tan Jie Hui believe Venture’s shares could find “support” at their FY2025 book value per share ...

Now that PacBio has broken through the $1 level that avoids Nasdaq delisting for now, we can focus on what might be ahead: ...